Amadix develops cancer diagnostics with a focus on non-invasive screening and early detection. It aims to detect tumors years before symptoms and provide screening signatures in blood to address unmet needs in oncology. Its most advanced product, Colofast, is a blood-based signature for colorectal cancer and advanced adenoma screening, designed to reduce mortality from colon cancer by enabling early intervention. The company pursues analytical validation and demonstration of clinical validity and utility through international multicentre studies, with plans for worldwide commercialization. The leadership combines experience in oncology diagnostics, pharmaceuticals, biotechnology, and intellectual property, and independent board members provide guidance on strategy, commercialization, and business development in Europe and the US.
Transbiomed is a biotechnology company based in Barcelona, Spain, specializing in non-invasive molecular diagnostic therapies. The company has developed a urine test designed for the early diagnosis of prostate cancer, positioning it as an alternative to traditional biopsy methods. Transbiomed is currently focused on the clinical validation of its innovative diagnostic approach across various hospitals in Spain. The company's strategy encompasses the discovery and development of biomarkers, advancing through industrial prototyping, product design, and pivotal clinical trials. Following these stages, Transbiomed aims to license its products to major pharmaceutical firms for commercialization. The company plans to initiate the commercialization of its prostate cancer diagnostic device by 2013.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.